




RealRate

PHARMACEUTICAL 2019

NovaBay Pharmaceuticals Inc.
Rank 254 of 371



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of NovaBay Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NovaBay Pharmaceuticals Inc. compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 485% points. The greatest weakness of NovaBay Pharmaceuticals Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 551% points.

The company's Economic Capital Ratio, given in the ranking table, is -307%, being 24% points above the market average of -331%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 8,608 |
| Cost of Goods Sold | 1,503 |
| Intangible Assets | 0 |
| Liabilities, Current | 3,847 |
| Liabilities, Non-Current | 198 |
| Other Assets | 552 |
| Other Compr. Net Income | 0 |
| Other Expenses | 11,482 |
| Other Liabilities | 362 |
| Other Net Income | 19 |
| Property and Equipment | 201 |
| Research and Development | 259 |
| Revenues | 12,508 |
| Selling, General and Administrative Expense | 5,828 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 9,361 |
| Liabilities | 4,407 |
| Expenses | 19,072 |
| Stockholders Equity | 4,954 |
| Net Income | -6,545 |
| Comprehensive Net Income | -6,545 |
| Economic Capital Ratio | -307% |